RISEDRONATE S.K.

País: Israel

Idioma: anglès

Font: Ministry of Health

Compra'l ara

ingredients actius:

RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE

Disponible des:

K.S.KIM INTERNATIONAL (SK- PHARMA) LTD., ISRAEL

Codi ATC:

M05BA07

formulario farmacéutico:

TABLETS

Composición:

RISEDRONIC ACID AS SODIUM HEMIPENTAHYDRATE 150 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricat per:

PHARMSCIENCE INC., CANADA

Área terapéutica:

RISEDRONIC ACID

indicaciones terapéuticas:

Treatment of postmenopausal osteoporosis. Prevention of postmenopausal osteoporosis.

Data d'autorització:

2022-10-31

Informació per a l'usuari

                                PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS
(PREPARATIONS( - 1986
The medicine is dispensed with a doctor’s prescription only.
RISEDRONATE S.K.
Tablets
Composition:
Each
Risedronate S.K.
tablet contains: Risedronate sodium 150 mg
For the list of inactive and allergenic ingredients in the
preparation, see section 2 “Important
information regarding some of the ingredients of the medicine” and
section 6 “Further
information”.
Read the leaflet carefully in its entirety before using the medicine.
This leaflet contains
concise information about the medicine. If you have further questions,
refer to the doctor or
pharmacist.
This medicine has been prescribed to treat your ailment. Do not pass
it on to others. It may
harm them even if it seems to you that their medical condition is
similar.
This medicine is usually not intended for children or adolescents
below 18 years of age.
1.
WHAT IS THE MEDICINE INTENDED FOR?
This medicine is intended for the treatment and prevention of
osteoporosis in postmenopausal
women. Therapeutic group: This medicine belongs to the therapeutic
group of
bisphosphonates.
2. BEFORE USING THE MEDICINE
Do not use the medicine if:
•
you are sensitive (allergic) to the active ingredient or to any of the
additional ingredients
contained in the medicine - see also section 6 “Further
Information”.
•
you have certain esophagus problems.
•
you are unable to remain in an upright position (sitting or standing)
for at least 30
minutes after taking the medicine.
•
you are in a state of hypocalcemia (low levels of blood calcium)
Special warnings regarding use of the medicine
Before treatment with
Risedronate S.K.
, inform the doctor if:
•
you are suffering from swallowing problems.
•
you are suffering from digestive problems.
•
you have low blood calcium levels. In this condition, the doctor may
prescribe for you
calcium and vitamin D supplements during the course of treatment with
Risedronate
S.K.
.
•
you plan to have dental surgery or a tooth extra
                                
                                Llegiu el document complet
                                
                            

Documents en altres idiomes

Informació per a l'usuari Informació per a l'usuari àrab 27-12-2023
Informació per a l'usuari Informació per a l'usuari hebreu 16-11-2023

Cerqueu alertes relacionades amb aquest producte

Veure l'historial de documents